A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IRB / irbesartan

[Related PubMed/MEDLINE]
Total Number of Papers: 61
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IRB  (>> Co-occurring Abbreviation)
Long Form:   irbesartan
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Irbesartan mitigates acute liver injury, oxidative stress, and apoptosis induced by acetaminophen in mice. Bax, Bcl-2, CYP2E1, i.p, NF-kappaB, TNF-alpha
2019 An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. AML, ARBs, AUC, ROS, Vd
2019 Free chlorine reactions of angiotensin II receptor antagonists: Kinetics study, transformation products elucidation and in-silico ecotoxicity assessment. LC, LOS, TEL, TOF, TPs, VAL
2019 Irbesartan suppresses cardiac toxicity induced by doxorubicin via regulating the p38-MAPK/NF-kappaB and TGF-beta1 pathways. DOX, NF-kappaB, NO, p38 MAPK, TGF-beta1, TNF-alpha
2019 Modeling the drug release from reduced graphene oxide-reinforced hyaluronic acid/gelatin/poly(ethylene oxide) polymeric films. Gel, HyA, PEO, rGO
2019 Research on cardioprotective effect of irbesartan in rats with myocardial ischemia-reperfusion injury through MAPK-ERK signaling pathway. AST, Bax, Bcl-2, CK-MB, cTnT, ELISA, ERK, FITC/PI, LDH, MAPK, MIRI, mRNA, RT-PCR
2019 Selective and validated kinetic spectrophotometric method for the determination of irbesartan in pure and pharmaceutical formulations. MBTH
2018 Antioxidant-Based Eutectics of Irbesartan: Viable Multicomponent Forms for the Management of Hypertension. DEXA, EMs
2018 Protective effect of irbesartan against doxorubicin-induced nephrotoxicity in rats: implication of AMPK, PI3K/Akt, and mTOR signaling pathways. AMPK, DOX, mTOR, PI3K
10  2018 Sorption of citalopram, irbesartan and fexofenadine in soils: Estimation of sorption coefficients from soil properties. BCS, CIT, FEX, SCS
11  2017 Exploring the interactions of irbesartan and irbesartan-2-hydroxypropyl-beta-cyclodextrin complex with model membranes. DPPC, DSC, ESI-MS, HP-beta-CD, MD, SAXS, SSNMR
12  2017 Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-gamma, AMPK/Akt/mTOR signaling and autophagy. ARBs
13  2016 Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)-irbesartan complex: structure-antihypertensive activity relationships in Cu(II)-sartan complexes. AT1, DFT
14  2016 Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-kappaB Pathway in Type 2 Diabetic db/db Mice. DN, FSGS, IgAN, MN, RANKL
15  2016 Micellar Electrokinetic Chromatography (MEKC) with Multiresponse Chemometric Optimization for the Determination of Hydrochlorothiazide and Coformulated Antihypertensives in the Presence of Hydrochlorothiazide Major Impurity. BISO, HCT, MEKC, SDS
16  2016 Production of Irbesartan Nanocrystals by High Shear Homogenisation and Ultra-Probe Sonication for Improved Dissolution Rate. BCS
17  2016 [Effect of the angiotensin II receptor antagonist (ARB), Irbesartan, on urinary markers in hypertensive patients]. L-FABP, UPC
18  2015 Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4. MCP-1, NE, ROS, TLR4, WT
19  2015 Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome. BP, MetS, TCM
20  2015 Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction. DRV, IS, LLOQ, MRM, SLE
21  2015 Hydroxypropyl-beta-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs. ASD, DLS, DSC, PXRD, SEM
22  2015 Irbesartan attenuates production of high-mobility group box 1 in response to lipopolysaccharide via downregulation of interferon-beta production. HMGB1, LPS, NO
23  2015 Irbesartan, an angiotensin II receptor antagonist, with selective PPAR-gamma-modulating activity improves function and structure of chemotherapy-damaged ovaries in rats. CYP, MDA, MPO, PPARgamma, SOD
24  2015 Mean centering of ratio spectra and concentration augmented classical least squares in a comparative approach for quantitation of spectrally overlapped bands of antihypertensives in formulations. CAN, CRACLS, HCT, MCR
25  2015 New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. IS
26  2015 The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study. AML, ARB, BP, eGFR
27  2014 A novel dilute and shoot HPLC assay method for quantification of irbesartan and hydrochlorothiazide in combination tablets and urine using second generation C18-bonded monolithic silica column with double gradient elution. HCT
28  2014 HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets. HCT
29  2014 Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors. Ang, AT1R, BK, CF, dLVP, iIRB, iLOS, IM, LOS, LVEDP
30  2014 Quality by design approach for oral bioavailability enhancement of irbesartan by self-nanoemulsifying tablets. DoE, PCA, SNEDDS, SNETs
31  2014 Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. ESI, HCTZ, LLOQ, RSD
32  2014 Simultaneous determination of some anti-hypertensive drugs in their binary mixture by novel spectrophotometric methods. CC, HCT, RD, RS-CM
33  2013 Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. EndMT, FSP1, HAECs, HG
34  2013 Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in Beagle dogs after oral administration at two dose rates. PK/PD, SBP
35  2012 Spectrofluorimetric method for determination of some angiotensin II receptor antagonists. AIIRA's, Cand, HCTZ, RFI, VAL
36  2011 Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. SNEDDS
37  2011 Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients. ARB, CR, HR, LOS, OM, VAL
38  2011 Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ASP, MCAO, SOD, TBARS
39  2011 Spectroscopic and spectrofluorimetric studies on the interaction of irbesartan with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and iodine. DDQ
40  2010 Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats. ALA, Ang, DNP, STZ
41  2010 Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations. HCTZ
42  2009 Preformulation study of the inclusion complex irbesartan-beta-cyclodextrin. beta-CD
43  2009 Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility. ---
44  2009 TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. Ang, AT1R, IKKbeta, IR, OZRs, Ser, TBK1, Tyr
45  2008 ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. AML, Ang II, IL-6, LZRs, NASH, OZRs, RAS, TGF-beta1, TNF-alpha
46  2008 Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy. ACE, Ang, DNP, i.p, STZ
47  2008 Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). AEs, ARB, ESRD, HD, MSupSBP, VAL
48  2007 Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. Ang II, CAD, LDL, MDA, oxLDL, sPLA2-IIA
49  2007 AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. CAD
50  2006 Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells. Ang II, AT, CTGF, CTGF AS
51  2006 Effects of isoliensinine on angiotensin II-induced proliferation of porcine coronary arterial smooth muscle cells. Ang II, bFGF, CASMCs, IL, PDGF
52  2005 Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats. ACo, HR, MAP, SO
53  2004 Effect of irbesartan on angiotensin II-induced hypertrophy of human proximal tubular cells. ACEIs, Ang II, FACS, RAS
54  2004 Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ACo, HR, SO
55  2004 The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. B1R, LV, MI
56  2003 Demonstration of altered fibroblast contractile activity in hypertensive heart disease. Ang II, HHD, SHR, WKY
57  2003 Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. ATII, PRO
58  2003 Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. 24hUpro, AG, BG, BW, Ccr, CTGF, GBM, KW, RTP, SD, STZ, TGF-beta1, Ualb, VG
59  2003 [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats]. 24hUpro, BG, BW, Ccr, CTGF, GBM, KW, RTP, SD, STZ, Ualb
60  2002 Angiotensin II subtype 1 (AT1) receptors contribute to ischemic contracture and regulate chemomechanical energy transduction in isolated transgenic rat (alphaMHC-hAT1)594-17 hearts. AT1, CF, LVDP, SD
61  2002 Determination of irbesartan in the presence of hydrochlorothiazide by derivative spectrophotometry. HCT